Abemaciclib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma
Conditions
Sarcoma, Dedifferentiated Liposarcoma
Trial Timeline
Jul 1, 2016 → Jul 1, 2026
NCT ID
NCT02846987About Abemaciclib
Abemaciclib is a phase 2 stage product being developed by Eli Lilly for Sarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT02846987. Target conditions include Sarcoma, Dedifferentiated Liposarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792725 | Pre-clinical | Completed |
| NCT03763604 | Pre-clinical | Completed |
| NCT06025747 | Phase 1 | Recruiting |
| NCT06678269 | Phase 1 | Recruiting |
| NCT04003896 | Phase 2 | Terminated |
| NCT04408924 | Phase 2 | Completed |
| NCT04681768 | Pre-clinical | Completed |
| NCT03891784 | Phase 2 | Active |
| NCT03837821 | Phase 1 | Active |
| NCT03339843 | Phase 2 | Completed |
| NCT03703466 | Phase 2 | Completed |
| NCT03310879 | Phase 2 | Recruiting |
| NCT02919696 | Phase 1 | Completed |
| NCT03130439 | Phase 2 | Terminated |
| NCT02981940 | Phase 2 | Active |
| NCT02846987 | Phase 2 | Active |
| NCT02482935 | Phase 1 | Completed |
| NCT02308020 | Phase 2 | Completed |
| NCT02387814 | Phase 1 | Completed |
| NCT02102490 | Phase 2 | Completed |
Competing Products
20 competing products in Sarcoma